If you ask someone who has tried the so-called "buyshroomscanada" what the experience was like, many will say that it is life-changing. It turns out that this is not just the wrath of the hallucinogen's mind. In fact, a growing group of researchers is excited about the potential benefits of psilocybin, the main hallucinogenic compound in magic mushrooms. This shows that it can help people overcome difficult (or drug resistance) and life-threatening problems. Destructive conditions such as addiction and major depression.
However, since 1970, psilocybin has been classified as a Schedule 1 illicit drug, a medical application that is not currently accepted in the United States and is defined as likely to be abused. So why has the interest in psilocybin revived recently, and what do research show in terms of benefits, mechanism of action, and even safety? This is a lowdown, but first, there is a history lesson:
"Magic Mushroom: A Long and Strange Journey Over Time"
Magic mushrooms have been used in a variety of mental and medical rituals for over 10,000 years due to their ability to change consciousness and induce mystical experiences.
As the story progressed, American banker and mushroom enthusiast R. Gordon Wasson was on vacation in Mexico with his wife in 1955. He brought some of the mushrooms back to his home in New York City and then shared his experience in Mexico in an article in Life magazine published in 1957. LSD is a chemically similar psychedelic drug, but about 1,000 times more powerful. Ability to treat alcoholism and other mental illnesses. (A dose of 25 mg psilocybin is equivalent to about 250 micrograms of LSD.)
Three years later, two Harvard psychologists, Timothy Leary and Richard Alpert, began investigating how psychedelics affect cognition, perception, and emotion. They started the infamous Harvard Psilocybin project and administered psilocybin to student volunteers to document its effects. Remember that psilocybin and LSD were legal at the time, but both Really and Alpert stumbled during the experiment and were eventually fired in 1963.
On the other hand, psychedelics have gained a reputation for being dangerous in mainstream culture. Many states began banning its use, and in 1970 Congress passed the Controlled Substances Act, classifying both psilocybin and LSD as Schedule 1 drugs. Both became illegal, so there was no funding for psychedelic research and research was injected.
But it didn't stop altogether, and decades of discoveries slowly piled up, demonstrating the benefits of psilocybin. In 2018, the FDA focused on researching its ability to alleviate treatment-resistant depression and named it breakthrough therapy. This is a classification that indicates important therapeutic potential and has accelerated the development and review process.
As another sign of clinical therapeutic potential, Johns Hopkins University launched the Psychedelic Consciousness Research Center in September 2019. The study continues to show the therapeutic benefits of psychedelics. Several other reputable centers for psychedelic research have also emerged, including the Psychedelic Center for Neural Science at Massachusetts General Hospital and the Imperial Psychedelic Research Program at Imperial College London.